{
    "abstract": "Background This study evaluated the immunogenicity and safety of a licensed meningococcal serogroup B vaccine (4CMenB) administered alone according to reduced schedules in infants or catch-up series in children. Methods In this open-label, multicentre, phase 3b study (NCT01339923), infants randomised 1:1:1 received 4CMenB: 2\u00a0+\u00a01 doses at 3\u00bd\u20135\u201311\u00a0months or 6\u20138\u201311\u00a0months of age, 3\u00a0+\u00a01 doses at ages 2\u00bd\u20133\u00bd\u20135\u201311\u00a0months. Children aged 2\u201310\u00a0years received 2 catch-up doses administered 2\u00a0months apart. Immune responses were measured by hSBA assays against 4 strains specific for vaccine components fHbp, NadA, PorA and NHBA. Sufficiency of immune responses was defined in groups with 2\u00a0+\u00a01 doses schedules as a lower limit \u226570% for the 97.5% confidence interval of the percentage of infants with hSBA titres \u22654, 1\u00a0month post-dose 2 for fHbp, NadA, PorA. Adverse events were collected for 7\u00a0days post-vaccination; serious adverse events (SAEs) throughout the study. Results 754 infants and 404 children were enrolled. Post-primary vaccination, 98\u2013100% of infants across all groups developed hSBA titres \u22654 for fHbp, NadA, PorA, and 48\u201377% for NHBA. Sufficiency of immune responses in infants receiving 2\u00a0+\u00a01 schedules was demonstrated for fHbp, NadA, PorA after 2 doses of 4CMenB, as pre-specified criteria were met. Following receipt of 2 catch-up doses, 95\u201399% of children developed hSBA titres \u22654 for 4CMenB components. Similar safety profiles were observed across groups. A total of 45 SAEs were reported, 3 of which were related to vaccination. Conclusion Reduced infant schedules and catch-up series in children were immunogenic and safe, having the potential to widen 4CMenB vaccine coverage. Funding GlaxoSmithKline Biologicals SA.",
    "author_highlights": [
        {
            "endOffset": 17938,
            "sentence": "Reduced 2 + 1 dose schedules of 4CMenB in infants were assessed.",
            "startOffset": 17874
        },
        {
            "endOffset": 18024,
            "sentence": "Two catch-up doses of 4CMenB were administered 2 months apart in children 2\u201310 years.",
            "startOffset": 17939
        },
        {
            "endOffset": 18114,
            "sentence": "\u226588% of vaccinated infants achieved seroprotective antibody levels for 4CMenB components.",
            "startOffset": 18025
        },
        {
            "endOffset": 18194,
            "sentence": "\u226595% of children achieved seroprotective antibody levels for 4CMenB components.",
            "startOffset": 18115
        },
        {
            "endOffset": 18246,
            "sentence": "No safety signals were identified during the study.",
            "startOffset": 18195
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": {
            "authors": [
                {
                    "first": "Federico",
                    "initial": "F.",
                    "last": "Martin\u00f3n-Torres"
                }
            ],
            "doi": "10.1016/j.jadohealth.2016.03.041",
            "firstpage": "S12",
            "issn": "1054139X",
            "lastpage": "S20",
            "pmid": "27449145",
            "pub_year": 2016,
            "title": "Deciphering the Burden of Meningococcal Disease: Conventional and Under-recognized Elements",
            "volume": "59"
        },
        "b0015": {
            "authors": [
                {
                    "first": "Rabab Z.",
                    "initial": "R.Z.",
                    "last": "Jafri"
                },
                {
                    "first": "Asad",
                    "initial": "A.",
                    "last": "Ali"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Carol",
                    "initial": "C.",
                    "last": "Tevi-Benissan"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Durrheim"
                },
                {
                    "first": "Juhani",
                    "initial": "J.",
                    "last": "Eskola"
                },
                {
                    "first": "Florence",
                    "initial": "F.",
                    "last": "Fermon"
                },
                {
                    "first": "Keith P.",
                    "initial": "K.P.",
                    "last": "Klugman"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                },
                {
                    "first": "Samba",
                    "initial": "S.",
                    "last": "Sow"
                },
                {
                    "first": "Shao",
                    "initial": "S.",
                    "last": "Zhujun"
                },
                {
                    "first": "Zulfiqar A.",
                    "initial": "Z.A.",
                    "last": "Bhutta"
                },
                {
                    "first": "Jon",
                    "initial": "J.",
                    "last": "Abramson"
                }
            ],
            "doi": "10.1186/1478-7954-11-17",
            "issn": "14787954",
            "pub_year": 2013,
            "title": "Global epidemiology of invasive meningococcal disease",
            "volume": "11"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Susanne P.",
                    "initial": "S.P.",
                    "last": "Stoof"
                },
                {
                    "first": "Gerwin D.",
                    "initial": "G.D.",
                    "last": "Rodenburg"
                },
                {
                    "first": "Mirjam J.",
                    "initial": "M.J.",
                    "last": "Knol"
                },
                {
                    "first": "Lidewij W.",
                    "initial": "L.W.",
                    "last": "R\u00fcmke"
                },
                {
                    "first": "Sandra",
                    "initial": "S.",
                    "last": "Bovenkerk"
                },
                {
                    "first": "Guy A.M.",
                    "initial": "G.A.M.",
                    "last": "Berbers"
                },
                {
                    "first": "Lodewijk",
                    "initial": "L.",
                    "last": "Spanjaard"
                },
                {
                    "first": "Arie",
                    "initial": "A.",
                    "last": "Van Der Ende"
                },
                {
                    "first": "Elisabeth A.M.",
                    "initial": "E.A.M.",
                    "last": "Sanders"
                }
            ],
            "doi": "10.1093/cid/civ506",
            "firstpage": "1281",
            "issn": "10584838",
            "lastpage": "1292",
            "pmid": "26123933",
            "pub_year": 2015,
            "title": "Disease Burden of Invasive Meningococcal Disease in the Netherlands between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex",
            "volume": "61"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Merijn W.",
                    "initial": "M.W.",
                    "last": "Bijlsma"
                },
                {
                    "first": "Matthijs C.",
                    "initial": "M.C.",
                    "last": "Brouwer"
                },
                {
                    "first": "Lodewijk",
                    "initial": "L.",
                    "last": "Spanjaard"
                },
                {
                    "first": "Diederik Van De",
                    "initial": "D.V.D.",
                    "last": "Beek"
                },
                {
                    "first": "Arie Van Der",
                    "initial": "A.V.D.",
                    "last": "Ende"
                }
            ],
            "doi": "10.1093/cid/ciu601",
            "firstpage": "1216",
            "issn": "10584838",
            "lastpage": "1221",
            "pmid": "25069869",
            "pub_year": 2014,
            "title": "A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination",
            "volume": "59"
        },
        "b0030": {
            "authors": [
                {
                    "first": "Andromachi",
                    "initial": "A.",
                    "last": "Karachaliou"
                },
                {
                    "first": "Andrew J.K.",
                    "initial": "A.J.K.",
                    "last": "Conlan"
                },
                {
                    "first": "Marie Pierre",
                    "initial": "M.P.",
                    "last": "Preziosi"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                }
            ],
            "doi": "10.1093/cid/civ508",
            "firstpage": "S594",
            "issn": "10584838",
            "lastpage": "S600",
            "pmid": "26553693",
            "pub_year": 2015,
            "title": "Modeling long-term vaccination strategies with MenAfriVac in the African Meningitis Belt",
            "volume": "61"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Shruti",
                    "initial": "S.",
                    "last": "Sridhar"
                },
                {
                    "first": "Brian",
                    "initial": "B.",
                    "last": "Greenwood"
                },
                {
                    "first": "Christopher",
                    "initial": "C.",
                    "last": "Head"
                },
                {
                    "first": "Stanley A.",
                    "initial": "S.A.",
                    "last": "Plotkin"
                },
                {
                    "first": "Marco A.",
                    "initial": "M.A.",
                    "last": "S\u00e1fadi"
                },
                {
                    "first": "Samir",
                    "initial": "S.",
                    "last": "Saha"
                },
                {
                    "first": "Muhamed Kheir",
                    "initial": "M.K.",
                    "last": "Taha"
                },
                {
                    "first": "Oyewale",
                    "initial": "O.",
                    "last": "Tomori"
                },
                {
                    "first": "Bradford D.",
                    "initial": "B.D.",
                    "last": "Gessner"
                }
            ],
            "doi": "10.1016/S1473-3099(15)00217-0",
            "firstpage": "1334",
            "issn": "14733099",
            "lastpage": "1346",
            "pmid": "26453240",
            "pub_year": 2015,
            "title": "Global incidence of serogroup B invasive meningococcal disease: A systematic review",
            "volume": "15"
        },
        "b0040": {
            "authors": [
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Gian Vincenzo",
                    "initial": "G.V.",
                    "last": "Zuccotti"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Michelangelo",
                    "initial": "M.",
                    "last": "Barone"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                }
            ],
            "doi": "10.4161/hv.29218",
            "firstpage": "2005",
            "issn": "21645515",
            "lastpage": "2014",
            "pmid": "25424810",
            "pub_year": 2014,
            "title": "A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II): Effects of variations of the OMV and protein content on immunogenicity and reactogenicity",
            "volume": "10"
        },
        "b0045": {
            "authors": [
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Dawson"
                },
                {
                    "first": "Ann",
                    "initial": "A.",
                    "last": "Holland"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "Evans"
                },
                {
                    "first": "Karen L.",
                    "initial": "K.L.",
                    "last": "Telford"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Oster"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Miller"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1086/656741",
            "firstpage": "1127",
            "issn": "10584838",
            "lastpage": "1137",
            "pmid": "20954968",
            "pub_year": 2010,
            "title": "Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy",
            "volume": "51"
        },
        "b0050": {
            "authors": [
                {
                    "first": "Nicoletta",
                    "initial": "N.",
                    "last": "Gossger"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Finn"
                },
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Nicola",
                    "initial": "N.",
                    "last": "Principi"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Etienne",
                    "initial": "E.",
                    "last": "Sokal"
                },
                {
                    "first": "Birgitta",
                    "initial": "B.",
                    "last": "Becker"
                },
                {
                    "first": "Dorothee",
                    "initial": "D.",
                    "last": "Kieninger"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1001/jama.2012.85",
            "firstpage": "573",
            "issn": "00987484",
            "lastpage": "582",
            "pmid": "22318278",
            "pub_year": 2012,
            "title": "Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: A randomized controlled trial",
            "volume": "307"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Gian Vincenzo",
                    "initial": "G.V.",
                    "last": "Zuccotti"
                },
                {
                    "first": "Fang",
                    "initial": "F.",
                    "last": "Xie"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.4161/hv.28666",
            "firstpage": "1993",
            "issn": "21645515",
            "lastpage": "2004",
            "pmid": "25424809",
            "pub_year": 2014,
            "title": "A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I): Effects of prophylactic paracetamol on immunogenicity and reactogenicity of routine infant vaccines and 4CMenB",
            "volume": "10"
        },
        "b0060": {
            "authors": [
                {
                    "first": "Timo",
                    "initial": "T.",
                    "last": "Vesikari"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Igor",
                    "initial": "I.",
                    "last": "Kohl"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Alan",
                    "initial": "A.",
                    "last": "Kimura"
                }
            ],
            "doi": "10.1016/S0140-6736(12)61961-8",
            "firstpage": "825",
            "issn": "01406736",
            "lastpage": "835",
            "pmid": "23324563",
            "pub_year": 2013,
            "title": "Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials",
            "volume": "381"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Christensen"
                },
                {
                    "first": "Caroline L.",
                    "initial": "C.L.",
                    "last": "Trotter"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Hickman"
                },
                {
                    "first": "W. John",
                    "initial": "W.J.",
                    "last": "Edmunds"
                }
            ],
            "doi": "10.1136/bmj.g5725",
            "issn": "09598146",
            "pmid": "25301037",
            "pub_year": 2014,
            "title": "Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: Modelling study",
            "volume": "349"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                }
            ],
            "doi": "10.1080/21645515.2015.1091131",
            "firstpage": "235",
            "issn": "21645515",
            "lastpage": "238",
            "pmid": "26619037",
            "pub_year": 2016,
            "title": "Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned?",
            "volume": "12"
        },
        "b0075": null,
        "b0080": {
            "authors": [
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Nick J.",
                    "initial": "N.J.",
                    "last": "Andrews"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sonia",
                    "initial": "S.",
                    "last": "Ribeiro"
                },
                {
                    "first": "Charlotte",
                    "initial": "C.",
                    "last": "Ward"
                },
                {
                    "first": "Joanne M.",
                    "initial": "J.M.",
                    "last": "White"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                }
            ],
            "doi": "10.1016/S0140-6736(16)31921-3",
            "firstpage": "2775",
            "issn": "01406736",
            "lastpage": "2782",
            "pmid": "28100432",
            "pub_year": 2016,
            "title": "Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study",
            "volume": "388"
        },
        "b0085": null,
        "b0090": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Helen",
                    "initial": "H.",
                    "last": "Campbell"
                },
                {
                    "first": "Sydel R.",
                    "initial": "S.R.",
                    "last": "Parikh"
                },
                {
                    "first": "Vanessa",
                    "initial": "V.",
                    "last": "Saliba"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mary",
                    "initial": "M.",
                    "last": "Ramsay"
                }
            ],
            "doi": "10.1016/j.jinf.2015.09.035",
            "firstpage": "611",
            "issn": "01634453",
            "lastpage": "614",
            "pmid": "26433141",
            "pub_year": 2015,
            "title": "The introduction of the meningococcal B (MenB) vaccine (Bexsero\u00ae) into the national infant immunisation programme - New challenges for public health",
            "volume": "71"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Miguel",
                    "initial": "M.",
                    "last": "O'Ryan"
                },
                {
                    "first": "Jeffrey",
                    "initial": "J.",
                    "last": "Stoddard"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                }
            ],
            "doi": "10.1007/s40265-013-0155-7",
            "firstpage": "15",
            "issn": "00126667",
            "lastpage": "30",
            "pmid": "24338083",
            "pub_year": 2014,
            "title": "A multi-component meningococcal serogroup B vaccine (4CMenB): The clinical development program",
            "volume": "74"
        },
        "b0100": {
            "authors": [
                {
                    "first": "Carl E.",
                    "initial": "C.E.",
                    "last": "Frasch"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Donnelly"
                }
            ],
            "doi": "10.1016/j.vaccine.2009.04.065",
            "firstpage": "B112",
            "issn": "0264410X",
            "lastpage": "B116",
            "pmid": "19464093",
            "pub_year": 2009,
            "title": "Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease",
            "volume": "27"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Marzia M.",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Davide",
                    "initial": "D.",
                    "last": "Serruto"
                },
                {
                    "first": "Francesca",
                    "initial": "F.",
                    "last": "Ferlicca"
                },
                {
                    "first": "Kay",
                    "initial": "K.",
                    "last": "Vienken"
                },
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Oster"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "John",
                    "initial": "J.",
                    "last": "Donnelly"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.05.014",
            "firstpage": "5023",
            "issn": "0264410X",
            "lastpage": "5030",
            "pmid": "20493284",
            "pub_year": 2010,
            "title": "Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus",
            "volume": "28"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Tom",
                    "initial": "T.",
                    "last": "Dawson"
                },
                {
                    "first": "Philipp",
                    "initial": "P.",
                    "last": "Oster"
                },
                {
                    "first": "Anita",
                    "initial": "A.",
                    "last": "Evans"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Brigitte",
                    "initial": "B.",
                    "last": "Ohene-Kena"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Ellen",
                    "initial": "E.",
                    "last": "Ypma"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1097/INF.0b013e3181f59f6d",
            "firstpage": "e71",
            "issn": "08913668",
            "lastpage": "e79",
            "pub_year": 2010,
            "title": "Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: A randomized comparative trial",
            "volume": "29"
        },
        "b0115": {
            "authors": [
                {
                    "first": "I.",
                    "initial": "I.",
                    "last": "Goldschneider"
                },
                {
                    "first": "E. C.",
                    "initial": "E.C.",
                    "last": "Gotschlich"
                },
                {
                    "first": "M. S.",
                    "initial": "M.S.",
                    "last": "Artenstein"
                }
            ],
            "doi": "10.1084/jem.129.6.1307",
            "firstpage": "1307",
            "issn": "00221007",
            "lastpage": "1326",
            "pmid": "4977280",
            "pub_year": 1969,
            "title": "Human immunity to the meningococcus. I. The role of humoral antibodies.",
            "volume": "129"
        },
        "b0120": {
            "authors": [
                {
                    "first": "Alessandro",
                    "initial": "A.",
                    "last": "Muzzi"
                },
                {
                    "first": "Marirosa",
                    "initial": "M.",
                    "last": "Mora"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Rino",
                    "initial": "R.",
                    "last": "Rappuoli"
                },
                {
                    "first": "Claudio",
                    "initial": "C.",
                    "last": "Donati"
                }
            ],
            "doi": "10.1128/mBio.00163-13",
            "issn": "21612129",
            "pmid": "23760461",
            "pub_year": 2013,
            "title": "Conservation of meningococcal antigens in the genus Neisseria",
            "volume": "4"
        },
        "b0125": {
            "authors": [
                {
                    "first": "Fiona",
                    "initial": "F.",
                    "last": "McQuaid"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Kelly"
                },
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Robinson"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Diego",
                    "initial": "D.",
                    "last": "D'Agostino"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1503/cmaj.141200",
            "firstpage": "E215",
            "issn": "08203946",
            "lastpage": "E223",
            "pmid": "25802309",
            "pub_year": 2015,
            "title": "Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months",
            "volume": "187"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Praveen",
                    "initial": "P.",
                    "last": "Saroey"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Robinson"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Kelly"
                },
                {
                    "first": "Nicoletta",
                    "initial": "N.",
                    "last": "Gossger"
                },
                {
                    "first": "Ly Mee",
                    "initial": "L.M.",
                    "last": "Yu"
                },
                {
                    "first": "Huajun",
                    "initial": "H.",
                    "last": "Wang"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1503/cmaj.130257",
            "firstpage": "E715",
            "issn": "08203946",
            "lastpage": "E724",
            "pmid": "24062178",
            "pub_year": 2013,
            "title": "Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose",
            "volume": "185"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Mildred A.",
                    "initial": "M.A.",
                    "last": "Iro"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Merryn",
                    "initial": "M.",
                    "last": "Voysey"
                },
                {
                    "first": "Sena",
                    "initial": "S.",
                    "last": "Jawad"
                },
                {
                    "first": "Adam",
                    "initial": "A.",
                    "last": "Finn"
                },
                {
                    "first": "Paul T.",
                    "initial": "P.T.",
                    "last": "Heath"
                },
                {
                    "first": "Gianni",
                    "initial": "G.",
                    "last": "Bona"
                },
                {
                    "first": "Susanna",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "Javier",
                    "initial": "J.",
                    "last": "Diez-Domingo"
                },
                {
                    "first": "Roman",
                    "initial": "R.",
                    "last": "Prymula"
                },
                {
                    "first": "Adefowope",
                    "initial": "A.",
                    "last": "Odueyungbo"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Dull"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.vaccine.2016.11.009",
            "firstpage": "395",
            "issn": "0264410X",
            "lastpage": "402",
            "pmid": "27914744",
            "pub_year": 2017,
            "title": "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24\u00a0months and immunogenicity of a fifth dose administered at 4\u00a0years of age-a phase 3 extension to a randomised controlled trial",
            "volume": "35"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Fiona",
                    "initial": "F.",
                    "last": "McQuaid"
                },
                {
                    "first": "Matthew D.",
                    "initial": "M.D.",
                    "last": "Snape"
                },
                {
                    "first": "Tessa M.",
                    "initial": "T.M.",
                    "last": "John"
                },
                {
                    "first": "Sarah",
                    "initial": "S.",
                    "last": "Kelly"
                },
                {
                    "first": "Hannah",
                    "initial": "H.",
                    "last": "Robinson"
                },
                {
                    "first": "Jennifer",
                    "initial": "J.",
                    "last": "Houlden"
                },
                {
                    "first": "Merryn",
                    "initial": "M.",
                    "last": "Voysey"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Toneatto"
                },
                {
                    "first": "Claudia",
                    "initial": "C.",
                    "last": "Kitte"
                },
                {
                    "first": "Peter M.",
                    "initial": "P.M.",
                    "last": "Dull"
                },
                {
                    "first": "Andrew J.",
                    "initial": "A.J.",
                    "last": "Pollard"
                }
            ],
            "doi": "10.1097/INF.0000000000000327",
            "firstpage": "760",
            "issn": "08913668",
            "lastpage": "766",
            "pmid": "24722351",
            "pub_year": 2014,
            "title": "Persistence of bactericidal antibodies to 5 years of age after immunization with serogroup B meningococcal vaccines at 6, 8, 12 and 40 months of age",
            "volume": "33"
        },
        "b0145": null,
        "b0150": {
            "authors": [
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                },
                {
                    "first": "Maria",
                    "initial": "M.",
                    "last": "Stella"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Wassil"
                }
            ],
            "doi": "10.1016/j.vaccine.2015.04.015",
            "firstpage": "2629",
            "issn": "0264410X",
            "lastpage": "2636",
            "pmid": "25882169",
            "pub_year": 2015,
            "title": "MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine",
            "volume": "33"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Giacomo",
                    "initial": "G.",
                    "last": "Frosi"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Morena Lo",
                    "initial": "M.L.",
                    "last": "Sapio"
                },
                {
                    "first": "Fabio",
                    "initial": "F.",
                    "last": "Rigat"
                },
                {
                    "first": "Stefanie",
                    "initial": "S.",
                    "last": "Gilchrist"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Duccio",
                    "initial": "D.",
                    "last": "Medini"
                }
            ],
            "doi": "10.1016/j.vaccine.2013.08.006",
            "firstpage": "4968",
            "issn": "0264410X",
            "lastpage": "4974",
            "pmid": "23954380",
            "pub_year": 2013,
            "title": "Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage",
            "volume": "31"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Shamez N.",
                    "initial": "S.N.",
                    "last": "Ladhani"
                },
                {
                    "first": "Marzia Monica",
                    "initial": "M.M.",
                    "last": "Giuliani"
                },
                {
                    "first": "Alessia",
                    "initial": "A.",
                    "last": "Biolchi"
                },
                {
                    "first": "Mariagrazia",
                    "initial": "M.",
                    "last": "Pizza"
                },
                {
                    "first": "Kazim",
                    "initial": "K.",
                    "last": "Beebeejaun"
                },
                {
                    "first": "Jay",
                    "initial": "J.",
                    "last": "Lucidarme"
                },
                {
                    "first": "Jamie",
                    "initial": "J.",
                    "last": "Findlow"
                },
                {
                    "first": "Mary E.",
                    "initial": "M.E.",
                    "last": "Ramsay"
                },
                {
                    "first": "Ray",
                    "initial": "R.",
                    "last": "Borrow"
                }
            ],
            "doi": "10.3201/eid2202.150369",
            "firstpage": "309",
            "issn": "10806040",
            "lastpage": "311",
            "pmid": "26811872",
            "pub_year": 2016,
            "title": "Effectiveness of meningococcal B vaccine against endemic hypervirulent neisseria meningitidis W strain, England",
            "volume": "22"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Jane",
                    "initial": "J.",
                    "last": "Whelan"
                },
                {
                    "first": "Hilde",
                    "initial": "H.",
                    "last": "Kl\u00f8vstad"
                },
                {
                    "first": "Inger Lise",
                    "initial": "I.L.",
                    "last": "Haugen"
                },
                {
                    "first": "Mirna",
                    "initial": "M.",
                    "last": "Robert-Du Ry van Beest Holle"
                },
                {
                    "first": "Jann",
                    "initial": "J.",
                    "last": "Storsaeter"
                }
            ],
            "doi": "10.3201/eid2206.151093",
            "firstpage": "1137",
            "issn": "10806040",
            "lastpage": "1139",
            "pmid": "27191543",
            "pub_year": 2016,
            "title": "Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway",
            "volume": "22"
        }
    },
    "body_text": [
        {
            "endOffset": 25161,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 25126,
                    "startOffset": 25122
                }
            },
            "secId": "s0020",
            "sentence": "Immune responses to each of the 4 vaccine components were assessed as the percentage of infants/children with serum bactericidal activity using human complement (hSBA) titres \u22654 (considered as protective [20]) against 4 MenB reference strains.",
            "startOffset": 24918,
            "title": "Study outcomes"
        },
        {
            "endOffset": 40063,
            "parents": [],
            "secId": "s0080",
            "sentence": "DT owns stock/stock options in the GSK group of companies.",
            "startOffset": 40005,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 29560,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Across all groups, 98%\u201399% of participants had hSBA titres \u22654 against the PorA test strain.",
            "startOffset": 29469,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 32111,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One infant in Group 3 with fever \u226540 \u00b0C was diagnosed with influenza 2 days post- booster vaccination.",
            "startOffset": 32009,
            "title": "Safety"
        },
        {
            "endOffset": 40848,
            "parents": [],
            "secId": "s0080",
            "sentence": "The institution of FMT received clinical trial fees from Novartis during the conduct of this study, and he received personal fees/non-financial support/grants/other from Pfizer, SPMSD and/or GSK, outside the submitted work.",
            "startOffset": 40625,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 39395,
            "parents": [],
            "secId": "s0065",
            "sentence": "These results support the potential protective benefit of the reduced and catch-up schedules in these age groups.",
            "startOffset": 39282,
            "title": "Conclusions"
        },
        {
            "endOffset": 37771,
            "parents": [],
            "secId": "s0060",
            "sentence": "As the 4CMenB vaccine targets genetically diverse meningococcal antigens, its effectiveness may vary depending on the level of expression and on the sequence identity of these particular proteins by each MenB strain.",
            "startOffset": 37555,
            "title": "Discussion"
        },
        {
            "endOffset": 25503,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Immune response in infants was defined as sufficient if, in terms of percentages of participants with hSBA titres \u22654 for fHbp, NadA and PorA, the lower limit (LL) of the 97.5% confidence interval [CI] was \u226570% at 1 month post-primary vaccination and the LL of the 95%CI was \u226575% at 1 month following booster vaccination in Groups 1, 2 and 3.",
            "startOffset": 25162,
            "title": "Study outcomes"
        },
        {
            "endOffset": 30337,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody GMTs against all strains declined between the primary series and the booster vaccination (Fig. 2).",
            "startOffset": 30230,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 36241,
            "parents": [],
            "secId": "s0060",
            "sentence": "Since the direct protection of infants through vaccination should remain a priority especially in Europe where the incidence of serogroup B meningococcal disease is the highest in this age category, an infant immunisation schedule followed by boosting in childhood and adolescence is needed to ensure continuous protection against the disease and may even increase the potential for herd immunity.",
            "startOffset": 35844,
            "title": "Discussion"
        },
        {
            "endOffset": 35456,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 35215,
                    "startOffset": 35211
                },
                "b0130": {
                    "endOffset": 35455,
                    "startOffset": 35451
                }
            },
            "secId": "s0060",
            "sentence": "Studies assessing the persistence of immune responses to 4CMenB showed that immunogenicity declines by 5 years of age [25], suggesting the need for further immunisations during childhood, but a booster dose at 40 months of age, following vaccination according to a 3 + 1 doses schedule (administered at 2, 4, 6, and 12 months) induces an anamnestic response [26].",
            "startOffset": 35093,
            "title": "Discussion"
        },
        {
            "endOffset": 21344,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 21343,
                    "startOffset": 21338
                },
                "b0020": {
                    "endOffset": 21343,
                    "startOffset": 21338
                }
            },
            "secId": "s0005",
            "sentence": "Case fatality ratios of IMD were estimated to 2% during the first year of life, 5\u20137% in children aged 1\u20135 years, 4% in children and adolescents aged 5\u201319 years, 8% in adults aged 20\u201365 years and 39% in adults over 65 years of age [2,4].",
            "startOffset": 21108,
            "title": "Introduction"
        },
        {
            "endOffset": 33603,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Neither AE was considered related to vaccination.",
            "startOffset": 33554,
            "title": "Safety"
        },
        {
            "endOffset": 30981,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "The criteria for sufficient immune response against the 3 reference strains for fHbp, NadA, and PorA were met in Groups 1\u20133 after receipt of both the primary series and the booster dose, and in Group 4 after receipt of the catch-up series (Tables S2 and 1).",
            "startOffset": 30724,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 35843,
            "parents": [],
            "refoffsets": {
                "b0125": {
                    "endOffset": 35842,
                    "startOffset": 35835
                },
                "b0140": {
                    "endOffset": 35842,
                    "startOffset": 35835
                }
            },
            "secId": "s0060",
            "sentence": "In several studies, the administration of additional doses of 4CMenB at the age of 5 years was shown to be immunogenic and well tolerated in previously vaccinated children [25,28].",
            "startOffset": 35663,
            "title": "Discussion"
        },
        {
            "endOffset": 31387,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Rates of systemic adverse reactions in infants were similar across the 3 groups and highest after the first vaccination.",
            "startOffset": 31267,
            "title": "Safety"
        },
        {
            "endOffset": 26753,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Serum samples from children were taken prior to first dose and 1 month post-second dose.",
            "startOffset": 26665,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 32741,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Unsolicited AEs were reported in 75%\u201379% of infants across the Groups 1\u20133, and 16%\u201325% were considered at least possibly related to vaccination (Table S2).",
            "startOffset": 32586,
            "title": "Safety"
        },
        {
            "endOffset": 32367,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Irritability (in 31%\u201337% of children following both doses), sleepiness (20%\u201328%), and arthralgia (19%\u201327%) were the most common systemic reactions in children aged 2\u20135 years, and myalgia (27%\u201329%) and malaise (23%\u201328%) in children aged 6\u201310 years (Fig. 4).",
            "startOffset": 32111,
            "title": "Safety"
        },
        {
            "endOffset": 21636,
            "parents": [],
            "refoffsets": {
                "b0025": {
                    "endOffset": 21635,
                    "startOffset": 21630
                },
                "b0030": {
                    "endOffset": 21635,
                    "startOffset": 21630
                }
            },
            "secId": "s0005",
            "sentence": "The introduction of meningococcal conjugate vaccines against MenC and MenA in routine paediatric immunisation programmes, with large catch-up campaigns including children, adolescents and young adults, has resulted in a substantial decrease of IMD incidence rates in several countries [5,6].",
            "startOffset": 21345,
            "title": "Introduction"
        },
        {
            "endOffset": 40341,
            "parents": [],
            "secId": "s0080",
            "sentence": "MAPS received research grant from the GSK group of companies, Pfizer and Takeda and speaker\u2019s honoraria from the GSK group of companies, Pfizer and Sanofi-Pasteur outside the submitted work.",
            "startOffset": 40151,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 22647,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 22619,
                    "startOffset": 22612
                },
                "b0080": {
                    "endOffset": 22619,
                    "startOffset": 22612
                }
            },
            "secId": "s0005",
            "sentence": "The campaign, monitored by the Public Health England, has already provided important data on both effectiveness and safety of this reduced vaccination schedule [15,16] and will continue to do so.",
            "startOffset": 22452,
            "title": "Introduction"
        },
        {
            "endOffset": 40624,
            "parents": [],
            "secId": "s0080",
            "sentence": "LYW reported personal fees as member of advisory board for the GSK group of companies, Novartis and MSD outside the submitted work.",
            "startOffset": 40493,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 28396,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Due to lack of prior data for responders in Group 2 for the strain specific to PorA, required responder rate for this strain was calculated to achieve overall power of 85%, 90% and 95% for the primary objective.",
            "startOffset": 28185,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 41686,
            "parents": [],
            "secId": "s0085",
            "sentence": "IM, MC, and DT contributed to the analysis and interpretation of data.",
            "startOffset": 41616,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 27364,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Infants and children were observed for 30 min after each vaccination.",
            "startOffset": 27295,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 25728,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Sufficient immune response in children was defined as a LL \u226570% for the 95%CI for the percentage of children achieving hSBA titres \u22654 for the 3 vaccine antigens, at 1 month after administration of the 2-dose catch-up series.",
            "startOffset": 25504,
            "title": "Study outcomes"
        },
        {
            "endOffset": 37190,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 37189,
                    "startOffset": 37180
                },
                "b0050": {
                    "endOffset": 37189,
                    "startOffset": 37180
                },
                "b0060": {
                    "endOffset": 37189,
                    "startOffset": 37180
                }
            },
            "secId": "s0060",
            "sentence": "Fever rates observed in our study were similar to those reported in previous trials [9,10,12].",
            "startOffset": 37096,
            "title": "Discussion"
        },
        {
            "endOffset": 41721,
            "parents": [],
            "secId": "s0085",
            "sentence": "IM provided statistical expertise.",
            "startOffset": 41687,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 35662,
            "parents": [],
            "refoffsets": {
                "b0135": {
                    "endOffset": 35661,
                    "startOffset": 35657
                }
            },
            "secId": "s0060",
            "sentence": "Waning of antibodies by the age of 4 years was also observed in children having received other 3 + 1 schedules, with antibody levels for each of the 4 vaccine components declining differently in time [27].",
            "startOffset": 35457,
            "title": "Discussion"
        },
        {
            "endOffset": 38901,
            "parents": [],
            "secId": "s0060",
            "sentence": "However, as there is currently no clinical efficacy correlate for MenB and the impact on carriage/herd immunity of the different schedules has not been estimated, the potential impact of the vaccine is still unknown.",
            "startOffset": 38685,
            "title": "Discussion"
        },
        {
            "endOffset": 27572,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Unsolicited adverse events (AEs) were also recorded for 7 days post-vaccination.",
            "startOffset": 27492,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 30023,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Of note, early responses were observed after the first vaccination in infants from subgroups 1b to 3b, when percentages of infants achieving hSBA titres \u22654 against reference strains were 62%\u201382% for fHbp, 91%\u201395% for NadA, 39%\u201343% for PorA, and 21%\u201336% for NHBA.",
            "startOffset": 29761,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41326,
            "parents": [],
            "secId": "s0085",
            "sentence": "All authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.",
            "startOffset": 41177,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 33705,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Three out of the 45 recorded SAEs were considered at least possibly related to vaccination (Table S2).",
            "startOffset": 33603,
            "title": "Safety"
        },
        {
            "endOffset": 36590,
            "parents": [],
            "secId": "s0060",
            "sentence": "Of note, the open-label design of the study might have biased the reporting of AEs towards higher reported incidences, and this could potentially impact any interpretation of the safety results.",
            "startOffset": 36396,
            "title": "Discussion"
        },
        {
            "endOffset": 38684,
            "parents": [],
            "secId": "s0060",
            "sentence": "Although vaccine efficacy was not measured in this study, the high percentages of infants and children with hSBA titres \u22654, together with the global estimates for strain coverages, indicate that the 4CMenB vaccine may be a powerful tool to reduce the burden of MenB IMD in these age groups.",
            "startOffset": 38394,
            "title": "Discussion"
        },
        {
            "endOffset": 27826,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Relatedness to the study vaccine and severity of AEs was determined by the investigator.",
            "startOffset": 27738,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 28982,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "A total of 754 infants and 404 children were enrolled; 94%\u201398% of participants across all groups completed the study (Fig. 1).",
            "startOffset": 28856,
            "title": "Demographics"
        },
        {
            "endOffset": 32586,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One child in the 6\u201310 years subgroup reported fever \u226540 \u00b0C on Day 7 following vaccination and was diagnosed with influenza, which resolved after 3 days.",
            "startOffset": 32434,
            "title": "Safety"
        },
        {
            "endOffset": 20902,
            "parents": [],
            "refoffsets": {
                "b0015": {
                    "endOffset": 20901,
                    "startOffset": 20898
                }
            },
            "secId": "s0005",
            "sentence": "Six of the 12 serogroups of Neisseria meningitidis (MenA, MenB, MenC, MenW, MenX, and MenY) are responsible for virtually all cases of IMD, with MenB, MenC, and MenY being prominent in the Americas and Europe, MenA and MenC in Asia, and MenA, MenC, MenX, and MenW in Africa [3].",
            "startOffset": 20624,
            "title": "Introduction"
        },
        {
            "endOffset": 24265,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Group 1 received primary vaccinations at 2\u00bd, 3\u00bd, and 5 months of age, Group 2 at 3\u00bd and 5 months of age, and Group 3 at 6 and 8 months of age.",
            "startOffset": 24123,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31481,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The most commonly reported local reaction in Group 4 was pain (85%\u201393% of children) (Fig. 4).",
            "startOffset": 31388,
            "title": "Safety"
        },
        {
            "endOffset": 26949,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Sera were stored at \u221220 \u00b0C until sent for analysis at GSK Clinical Sciences Laboratory, Marburg, Germany (NHBA) or Public Health England Laboratory, Manchester, United Kingdom (fHbp, NadA, PorA).",
            "startOffset": 26754,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 24123,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "A full list of the inclusion/exclusion criteria is presented in Text S1, Supplementary Material.",
            "startOffset": 24027,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37460,
            "parents": [],
            "refoffsets": {
                "b0055": {
                    "endOffset": 37459,
                    "startOffset": 37455
                }
            },
            "secId": "s0060",
            "sentence": "Previous studies have shown that co-administration of the vaccine with paracetamol can significantly reduce the incidence of fever and other local and systemic reactions without impacting the immunogenicity of 4CMenB or co-administered routine paediatric vaccines [11].",
            "startOffset": 37191,
            "title": "Discussion"
        },
        {
            "endOffset": 30488,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "One month post-booster booster vaccination, all infants (95%CI: 98%\u2013100%) in Groups 1 to 3 had hSBA titres \u22654 against fHbp and NadA reference strains.",
            "startOffset": 30338,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40150,
            "parents": [],
            "secId": "s0080",
            "sentence": "MAPS reported a grant from the GSK group of companies during the conduct of the study.",
            "startOffset": 40064,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 20623,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 20622,
                    "startOffset": 20617
                },
                "b0010": {
                    "endOffset": 20622,
                    "startOffset": 20617
                }
            },
            "secId": "s0005",
            "sentence": "Worldwide, invasive meningococcal disease (IMD) represents a significant burden, with a global case fatality rate of 5%\u201310%, even with antibiotic treatment [1,2].",
            "startOffset": 20461,
            "title": "Introduction"
        },
        {
            "endOffset": 33800,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Pyrexia, which resolved within 3 days of onset, was reported in 2 infants from Groups 1 and 2.",
            "startOffset": 33706,
            "title": "Safety"
        },
        {
            "endOffset": 38077,
            "parents": [],
            "refoffsets": {
                "b0150": {
                    "endOffset": 38076,
                    "startOffset": 38072
                }
            },
            "secId": "s0060",
            "sentence": "The mean coverage was estimated to range from 66% to 91% in 13 countries worldwide [30].",
            "startOffset": 37989,
            "title": "Discussion"
        },
        {
            "endOffset": 41155,
            "parents": [],
            "secId": "s0080",
            "sentence": "JCTT, PIM and ACM declare no conflict of interest.",
            "startOffset": 41105,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 34283,
            "parents": [],
            "secId": "s0060",
            "sentence": "This is the first study assessing the immunogenicity and safety of the 4CMenB vaccine administered alone according to a reduced 2 + 1 dose schedule in infants, and the first trial primarily designed to investigate administration of 4CMenB to children aged 2\u201310 years.",
            "startOffset": 34016,
            "title": "Discussion"
        },
        {
            "endOffset": 21880,
            "parents": [],
            "refoffsets": {
                "b0035": {
                    "endOffset": 21762,
                    "startOffset": 21759
                }
            },
            "secId": "s0005",
            "sentence": "The average incidence of MenB disease worldwide is estimated at 0.01\u20134.26 per 100,000 population, depending on the country [7]; therefore the introduction of a vaccine against MenB was an unmet medical need to reduce the burden of IMD globally.",
            "startOffset": 21636,
            "title": "Introduction"
        },
        {
            "endOffset": 31104,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "At least 1 solicited reaction was reported by 84%\u201397% of infants and children after any of the study vaccinations.",
            "startOffset": 30990,
            "title": "Safety"
        },
        {
            "endOffset": 39281,
            "parents": [],
            "secId": "s0065",
            "sentence": "Almost all infants and children in our study achieved seroprotective antibody levels, following any vaccine schedule, including the reduced dose schedules in young infants, and no safety signals were identified.",
            "startOffset": 39070,
            "title": "Conclusions"
        },
        {
            "endOffset": 33071,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In Group 4, fewer AEs were reported in children aged 6\u201310 years (34%) than in children aged 2\u20135 years (56%).",
            "startOffset": 32963,
            "title": "Safety"
        },
        {
            "endOffset": 28733,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "For a group size of 200 participants, the study had an estimated overall power of 97% for Group 3 and 80% for Group 2 (with an assumed responder rate of at least 79% for PorA) to demonstrate the sufficiency of the immune response against each of the 3 MenB test strains, 1 month post-primary vaccination with 4CMenB (primary objective).",
            "startOffset": 28397,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 24901,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0095": {
                    "endOffset": 24765,
                    "startOffset": 24761
                }
            },
            "secId": "s0015",
            "sentence": "The study vaccine [19] was administered alone intramuscularly into the outer side of the thigh (Groups 1\u20133) or deltoid area of the non-dominant arm (Group 4).",
            "startOffset": 24743,
            "title": "Study design and participants"
        },
        {
            "endOffset": 32963,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "For infants, the most commonly reported unsolicited AEs were induration lasting more than 7 days, reported in 23% of infants in Group 1, and upper respiratory tract infection, reported in 22% of infants in Groups 2 and 3.",
            "startOffset": 32742,
            "title": "Safety"
        },
        {
            "endOffset": 33208,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Induration (7% of children aged 2\u20135 years) and pyrexia (4% of children aged 6\u201310 years) were the most commonly reported unsolicited AEs.",
            "startOffset": 33072,
            "title": "Safety"
        },
        {
            "endOffset": 24743,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Infants/children in the same group received the same vaccination schedule and results were pooled for analysis.",
            "startOffset": 24632,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29199,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Demographic characteristics (ethnicity, gender) were similar across groups, while baseline characteristics such as height and weight varied across groups due to the age differences (Table S1, Supplementary Material).",
            "startOffset": 28983,
            "title": "Demographics"
        },
        {
            "endOffset": 41615,
            "parents": [],
            "secId": "s0085",
            "sentence": "FMT, MAPS, ACM, PIM, JCTT, LYW, and EDMJ contributed to the acquisition of data.",
            "startOffset": 41535,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 21107,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 21106,
                    "startOffset": 21103
                }
            },
            "secId": "s0005",
            "sentence": "Although IMD affects individuals of all age groups, the highest rates of disease are usually found in infants, with secondary peaks seen in adolescents and in adults >65 years of age in some countries [2].",
            "startOffset": 20902,
            "title": "Introduction"
        },
        {
            "endOffset": 23824,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at clinicaltrials.gov (NCT01339923).",
            "startOffset": 23764,
            "title": "Study design and participants"
        },
        {
            "endOffset": 40004,
            "parents": [],
            "secId": "s0080",
            "sentence": "MC was and, DT and IM are employees of the GSK group of companies.",
            "startOffset": 39938,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 27894,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "No formal statistical hypotheses were tested.",
            "startOffset": 27849,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 22152,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 22151,
                    "startOffset": 22145
                },
                "b0045": {
                    "endOffset": 22151,
                    "startOffset": 22145
                },
                "b0050": {
                    "endOffset": 22151,
                    "startOffset": 22145
                },
                "b0055": {
                    "endOffset": 22151,
                    "startOffset": 22145
                },
                "b0060": {
                    "endOffset": 22151,
                    "startOffset": 22145
                }
            },
            "secId": "s0005",
            "sentence": "A multi-component vaccine (4CMenB; Bexsero, GSK) is now licensed in 37 countries worldwide, and approved for use in a 3 + 1 dose schedule in young infants, a schedule shown to be immunogenic and to display a clinically acceptable safety profile in clinical trials [8\u201312].",
            "startOffset": 21881,
            "title": "Introduction"
        },
        {
            "endOffset": 32433,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Most cases of fever were considered mild or moderate in severity.",
            "startOffset": 32368,
            "title": "Safety"
        },
        {
            "endOffset": 22451,
            "parents": [],
            "refoffsets": {
                "b0070": {
                    "endOffset": 22450,
                    "startOffset": 22446
                }
            },
            "secId": "s0005",
            "sentence": "In the United Kingdom, 4CMenB has recently been introduced into the infant vaccination programme as a 2 + 1 dose schedule administered at 2, 4, and 12 months of age [14].",
            "startOffset": 22281,
            "title": "Introduction"
        },
        {
            "endOffset": 24322,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "All infants received a booster dose at 11 months of age.",
            "startOffset": 24266,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38189,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 38188,
                    "startOffset": 38184
                }
            },
            "secId": "s0060",
            "sentence": "However, MATS might underestimate the true neutralising capability of the vaccine-induced immune response [31].",
            "startOffset": 38078,
            "title": "Discussion"
        },
        {
            "endOffset": 30724,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "All infants (95%CI: 98%\u2013100%) in Groups 1 and 3, and 99% (95%CI: 96%\u2013100%) of infants in Group 2 had hSBA titres \u22654 against PorA reference strain, while 83%\u201387% of infants in Groups 1\u20133 had hSBA titres \u22654 against NHBA reference strain.",
            "startOffset": 30489,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 40492,
            "parents": [],
            "secId": "s0080",
            "sentence": "The institution of LYW received a grant from Novartis during the conduct of this study and from the GSK group of companies outside the submitted work.",
            "startOffset": 40342,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 24631,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Groups 1\u20133 were each randomised (1:1) using a web-based randomisation system into 2 sub-groups (a and b), and Group 4 was separated into 2 sub-groups based on age at enrolment (2\u20135 years [Group 4a] and 6\u201310 years [Group 4b]).",
            "startOffset": 24406,
            "title": "Study design and participants"
        },
        {
            "endOffset": 33970,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One infant in Group 3 developed juvenile idiopathic arthritis, which was reported after the study (110 days after the third vaccination) and was unresolved by study end.",
            "startOffset": 33801,
            "title": "Safety"
        },
        {
            "endOffset": 22837,
            "parents": [],
            "secId": "s0005",
            "sentence": "The current study was designed to investigate different immunisation schedules in infants in whom the 4CMenB vaccine could be administered alone either between or after routine vaccinations.",
            "startOffset": 22647,
            "title": "Introduction"
        },
        {
            "endOffset": 27255,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Geometric mean titres (GMTs) and 95%CIs, estimated using the Clopper-Pearson method, were calculated for each group at each timepoint.",
            "startOffset": 27121,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 37555,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 37554,
                    "startOffset": 37550
                }
            },
            "secId": "s0060",
            "sentence": "Moreover, rates of fever in real life experience are lower than those reported in trials [29].",
            "startOffset": 37461,
            "title": "Discussion"
        },
        {
            "endOffset": 24406,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Children in Group 4 received a 2-dose-catch-up series, administered 2 months apart.",
            "startOffset": 24323,
            "title": "Study design and participants"
        },
        {
            "endOffset": 31576,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Across all groups, no increased reactogenicity was observed following subsequent vaccinations.",
            "startOffset": 31482,
            "title": "Safety"
        },
        {
            "endOffset": 41534,
            "parents": [],
            "secId": "s0085",
            "sentence": "DT contributed to the study conception and design.",
            "startOffset": 41484,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 23110,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 23109,
                    "startOffset": 23102
                },
                "b0090": {
                    "endOffset": 23109,
                    "startOffset": 23102
                }
            },
            "secId": "s0005",
            "sentence": "Preliminary study results were already reviewed by the Joint Committee on Vaccination and Immunisation, and supported the recommendation to introduce a routine infant MenB immunisation programme according to a 2 + 1 dose schedule with concomitant routine vaccines [17,18].",
            "startOffset": 22838,
            "title": "Introduction"
        },
        {
            "endOffset": 30230,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "hSBA GMTs against the 4 test strains seemed similar across all groups at each time point, except for NHBA GMTs in Group 4, which were higher at baseline and after completion of the catch-up series (Fig. 2).",
            "startOffset": 30024,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 38394,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 38306,
                    "startOffset": 38302
                },
                "b0165": {
                    "endOffset": 38363,
                    "startOffset": 38359
                }
            },
            "secId": "s0060",
            "sentence": "The 4CMenB vaccine has also the potential to offer some cross-protection against non-B meningococcal serogroups [32], including against other bacteria of the same genus [33], with shared protein antigens.",
            "startOffset": 38190,
            "title": "Discussion"
        },
        {
            "endOffset": 32008,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Fever \u226540 \u00b0C was reported by less than 1% of infants and lasted for a maximum of 1 day, except for 1 infant in Group 1 who reported fever \u226540 \u00b0C on Day 6 after the second vaccination that resolved after 2 days.",
            "startOffset": 31798,
            "title": "Safety"
        },
        {
            "endOffset": 34743,
            "parents": [],
            "refoffsets": {
                "b0115": {
                    "endOffset": 34687,
                    "startOffset": 34683
                }
            },
            "secId": "s0060",
            "sentence": "Regardless of the schedule used nearly all infants and children in our study achieved seroprotective titres (hSBA titres \u22654) [23] against 3 MenB test strains following each vaccination.",
            "startOffset": 34558,
            "title": "Discussion"
        },
        {
            "endOffset": 39058,
            "parents": [],
            "secId": "s0060",
            "sentence": "The reduced number of doses offers greater flexibility to fit the administration of the 4CMenB vaccine into an already crowded infant immunisation schedule.",
            "startOffset": 38902,
            "title": "Discussion"
        },
        {
            "endOffset": 34557,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 34471,
                    "startOffset": 34462
                },
                "b0050": {
                    "endOffset": 34471,
                    "startOffset": 34462
                },
                "b0055": {
                    "endOffset": 34471,
                    "startOffset": 34462
                },
                "b0060": {
                    "endOffset": 34471,
                    "startOffset": 34462
                },
                "b0110": {
                    "endOffset": 34556,
                    "startOffset": 34552
                }
            },
            "secId": "s0060",
            "sentence": "The immune responses and safety profile of 4CMenB administered to infants in our study were similar to those previously reported following a 3 + 1 dose schedule in young infants [8,10\u201312], or a 3-dose schedule in older infants (6\u20138 months of age at first vaccination) [22].",
            "startOffset": 34284,
            "title": "Discussion"
        },
        {
            "endOffset": 27491,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and systemic adverse reactions were recorded for 7 days (Days 0\u20137) following each vaccination, by diary cards.",
            "startOffset": 27365,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 34940,
            "parents": [],
            "secId": "s0060",
            "sentence": "hSBA GMTs against the MenB test strains for the 4 vaccine components were similar across groups, except for NHBA GMTs that were higher in children than in infants both before and after vaccination.",
            "startOffset": 34743,
            "title": "Discussion"
        },
        {
            "endOffset": 28833,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "All statistical analyses were performed using SAS v9.1 or higher.",
            "startOffset": 28768,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 31266,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In Groups 1\u20133, the most commonly reported local reactions following vaccinations were tenderness (41%\u201353% of infants) and erythema (33%\u201342% of infants) (Fig. 3).",
            "startOffset": 31105,
            "title": "Safety"
        },
        {
            "endOffset": 39811,
            "parents": [],
            "secId": "s0070",
            "sentence": "Bexsero is a trademark of the GSK group of companies.",
            "startOffset": 39758,
            "title": "Trademark statement"
        },
        {
            "endOffset": 33553,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Two infants withdrew from the study following AEs: a congenital central nervous anomaly and muscle spasms were reported for 1 infant in Group 1, and 1 infant in Group 2 was withdrawn due to allergic colitis.",
            "startOffset": 33346,
            "title": "Safety"
        },
        {
            "endOffset": 41104,
            "parents": [],
            "secId": "s0080",
            "sentence": "EDM reported a grant from Novartis during the conduct of the study.",
            "startOffset": 41037,
            "title": "Declaration of interest"
        },
        {
            "endOffset": 29468,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "hSBA titres \u22654 against the reference strains specific to fHbp and NadA antigens were measured in all infants in Groups 1\u20133 at one month after completion of the primary series and in 99% of children in Group 4 after the 2-dose catch-up series (Table 1).",
            "startOffset": 29216,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 22280,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 22279,
                    "startOffset": 22275
                }
            },
            "secId": "s0005",
            "sentence": "Combined infant and adolescent vaccination strategies are estimated to have the greatest impact and can be cost-effective [13].",
            "startOffset": 22153,
            "title": "Introduction"
        },
        {
            "endOffset": 25965,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The primary objective of the study was to demonstrate a sufficient immune response to the 3 reference strains specific for fHbp, NadA and PorA at 1 month after the 2-dose primary vaccination series in healthy infants from Groups 2 and 3.",
            "startOffset": 25728,
            "title": "Study outcomes"
        },
        {
            "endOffset": 28768,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Safety was evaluated descriptively.",
            "startOffset": 28733,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 29760,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Bactericidal response to NHBA reference strain varied across the groups, with 59%, 49% and 77% of infants in Groups 1, 2, and 3, respectively, and 95% of children in Group 4 achieving hSBA titres \u22654.",
            "startOffset": 29561,
            "title": "Immunogenicity"
        },
        {
            "endOffset": 41483,
            "parents": [],
            "secId": "s0085",
            "sentence": "All authors reviewed and commented critically drafts of the manuscript for important intellectual content and gave final approval to submit for publication.",
            "startOffset": 41327,
            "title": "Authors\u2019 contributions"
        },
        {
            "endOffset": 26420,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives assessed the sufficiency of the immune responses induced by the 3-dose 4CMenB primary vaccination schedule in Group 1, the immune response elicited by a booster dose of 4CMenB in infants, the immunogenicity of the 2-dose catch-up series in children aged 2\u201310 years, sufficiency of the immune response induced by the fHbp, NadA, PorA vaccine components across all groups and timepoints, and the safety and tolerability of the vaccine.",
            "startOffset": 25966,
            "title": "Study outcomes"
        },
        {
            "endOffset": 23237,
            "parents": [],
            "secId": "s0005",
            "sentence": "The immunogenicity and safety of a 2-dose catch-up series of 4CMenB in healthy 2- to 10-year-old children were also evaluated.",
            "startOffset": 23111,
            "title": "Introduction"
        },
        {
            "endOffset": 36977,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 36976,
                    "startOffset": 36973
                },
                "b0045": {
                    "endOffset": 36794,
                    "startOffset": 36788
                },
                "b0050": {
                    "endOffset": 36862,
                    "startOffset": 36855
                },
                "b0060": {
                    "endOffset": 36862,
                    "startOffset": 36855
                }
            },
            "secId": "s0060",
            "sentence": "A higher reactogenicity of 4CMenB than expected was linked to the inclusion of outer membrane vesicles in the vaccine formulation [8], but the vaccine is still considered well tolerated in infants [8\u201310], even when co-administered with routine paediatric vaccines [10,12] and reducing the content in outer membrane vesicles was found to impact negatively the immunogenicity profile [8].",
            "startOffset": 36591,
            "title": "Discussion"
        },
        {
            "endOffset": 23534,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This randomised phase 3b, open-label study was conducted in 26 centres (4 in Brazil, 3 in Peru, 10 in Hungary, and 9 in Spain) between April 2011 and December 2014, in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice.",
            "startOffset": 23277,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36395,
            "parents": [],
            "secId": "s0060",
            "sentence": "Safety profiles were similar in all groups, with the highest reactogenicity observed after the first dose, and no associated safety signals were detected.",
            "startOffset": 36241,
            "title": "Discussion"
        },
        {
            "endOffset": 39739,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our study may have important public health implications, as both the reduced vaccine schedule in young infants and the administration of catch-up series in children up to 10 years of age have the potential to widen the use of the 4CMenB vaccine, diminish the costs of immunisation programmes, as well as improve vaccination schedule compliance.",
            "startOffset": 39395,
            "title": "Conclusions"
        },
        {
            "endOffset": 33345,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Most unsolicited AEs were reported in less than 2% of participants, were mild to moderate, and resolved by the time of study termination.",
            "startOffset": 33208,
            "title": "Safety"
        },
        {
            "endOffset": 26664,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples were collected from infants prior to first (Groups 1a to 3a) or second vaccination (Groups 1b to 3b), at 1 month post-primary vaccination, pre-booster vaccination, and 1 month post-booster vaccination.",
            "startOffset": 26449,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 37095,
            "parents": [],
            "secId": "s0060",
            "sentence": "As expected, the highest rates of fever were observed in infants, but most cases were mild to moderate and transient.",
            "startOffset": 36978,
            "title": "Discussion"
        },
        {
            "endOffset": 28184,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0045": {
                    "endOffset": 28183,
                    "startOffset": 28177
                },
                "b0110": {
                    "endOffset": 28183,
                    "startOffset": 28177
                }
            },
            "secId": "s0035",
            "sentence": "For the primary objective, the following assumptions were made based on results from previous clinical trials: the percentage of infants achieving titres \u22654 was considered to be \u226590% against strains for fHbp and NadA in Group 2 and against strains for fHbp, NadA and PorA in Group 3 [9,22].",
            "startOffset": 27894,
            "title": "Statistical analysis"
        },
        {
            "endOffset": 39915,
            "parents": [],
            "secId": "s0075",
            "sentence": "This work was supported by Novartis Vaccines and Diagnostics, now GlaxoSmithKline Biologicals SA.",
            "startOffset": 39818,
            "title": "Funding"
        },
        {
            "endOffset": 27120,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 27119,
                    "startOffset": 27115
                }
            },
            "secId": "s0025",
            "sentence": "Antibody responses to vaccine components were measured by hSBA against MenB reference strains: H44/76 for fHbp, 5/99 for NadA, M10713 for NHBA and NZ98/254 for PorA [21].",
            "startOffset": 26950,
            "title": "Immunogenicity assessments"
        },
        {
            "endOffset": 31797,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The most frequent systemic reactions in infants were fever (rectal temperature \u226538 \u00b0C) reported in 36%\u201355% of infants across all groups, unusual crying (34%\u201360%), sleepiness (25%\u201358%), and irritability (31%\u201352%) (Fig. 5).",
            "startOffset": 31576,
            "title": "Safety"
        },
        {
            "endOffset": 34005,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "There were no deaths in the study.",
            "startOffset": 33971,
            "title": "Safety"
        },
        {
            "endOffset": 27737,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Any reactions continuing after this time period, AEs leading to study withdrawal, medically attended AEs, or serious AEs (SAEs) were monitored throughout the study.",
            "startOffset": 27573,
            "title": "Safety and reactogenicity assessments"
        },
        {
            "endOffset": 23763,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The protocol and its amendments were approved by the institutional review boards and ethics committees for each site, and parents or legal guardians of all study participants provided written informed consent prior to enrolment.",
            "startOffset": 23535,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35093,
            "parents": [],
            "refoffsets": {
                "b0120": {
                    "endOffset": 35092,
                    "startOffset": 35088
                }
            },
            "secId": "s0060",
            "sentence": "As NHBA is conserved in nearly all strains of pathogenic MenB the higher baseline titres in children may be due to exposure to circulating strains [24].",
            "startOffset": 34941,
            "title": "Discussion"
        },
        {
            "endOffset": 24026,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy infants and children were enrolled in 4 study groups, by age at enrolment, without randomisation: approximately 2\u00bd (Group 1), 3\u00bd (Group 2) or 6 months of age (Group 3), and 2\u201310 years (Group 4).",
            "startOffset": 23824,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37988,
            "parents": [],
            "secId": "s0060",
            "sentence": "The potential global coverage of MenB strains by the 4CMenB vaccine has been assessed by the meningococcal antigen typing system (MATS) assay that evaluates the potential strain killing of vaccine-induced antibodies.",
            "startOffset": 37772,
            "title": "Discussion"
        },
        {
            "endOffset": 41036,
            "parents": [],
            "secId": "s0080",
            "sentence": "FMT\u2019s research activities have been supported by grants from Instituto Carlos III (Contrato de intensificaci\u00f3n de la actividad investigadora) from National Plan I + D + I and FEDER funds.",
            "startOffset": 40849,
            "title": "Declaration of interest"
        }
    ],
    "docId": "S0264410X1730631X",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "federico.martinon.torres@sergas.es",
                "first": "Federico",
                "initial": "F.",
                "last": "Martin\u00f3n-Torres"
            },
            {
                "email": "masafadi@uol.com.br",
                "first": "Marco Aurelio P.",
                "initial": "M.A.P.",
                "last": "Safadi"
            },
            {
                "email": "alfonsocarmona@ihppediatria.com",
                "first": "Alfonso Carmona",
                "initial": "A.C.",
                "last": "Martinez"
            },
            {
                "email": "InfanteP@vithas.es",
                "first": "Pilar Infante",
                "initial": "P.I.",
                "last": "Marquez"
            },
            {
                "email": "JCTEJEDOR@infonegocio.com",
                "first": "Juan Carlos Tejedor",
                "initial": "J.C.T.",
                "last": "Torres"
            },
            {
                "email": "lily.crie@epm.br",
                "first": "Lily Yin",
                "initial": "L.Y.",
                "last": "Weckx"
            },
            {
                "email": "edson@bahia.fiocruz.br",
                "first": "Edson Duarte",
                "initial": "E.D.",
                "last": "Moreira"
            },
            {
                "email": "ilhem.z.mensi@gsk.com",
                "first": "Ilhem",
                "initial": "I.",
                "last": "Mensi"
            },
            {
                "email": "marco.calabresi@gmail.com",
                "first": "Marco",
                "initial": "M.",
                "last": "Calabresi"
            },
            {
                "email": "daniela.x.toneatto@gsk.com",
                "first": "Daniela",
                "initial": "D.",
                "last": "Toneatto"
            }
        ],
        "doi": "10.1016/j.vaccine.2017.05.023",
        "firstpage": "3548",
        "issn": "0264410X",
        "keywords": [
            "4CMenB vaccination",
            "Catch-up dose",
            "Children",
            "Infants",
            "Reduced doses"
        ],
        "lastpage": "3557",
        "openaccess": "Full",
        "pub_year": 2017,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial"
    }
}